Formation bio launches $600 million fund to overcome AI drug development challenges

Formation Bio has launched a $600 million fund aimed at addressing the persistent challenge of drug development in the AI-driven biotech sector. The initiative, dubbed a 'drug development accelerator,' seeks to bridge the gap between AI's strength in drug discovery and its limitations in development. The fund will acquire molecules and drug programs, which Formation will then assist in advancing through the development pipeline. Each acquired company will operate as an independent NewCo, with potential early successes being sold to major pharmaceutical companies. This approach represents the latest evolution of the hub-and-spoke model in biotech innovation. The move underscores the growing role of AI in the pursuit of curing diseases, positioning it as a key solution to offset potential drawbacks in the industry.